Clinical teams are expanding cannabis-related neuropathic pain studies with an emphasis on standardized dosing and patient-reported outcomes.
Investigators are measuring symptom reduction alongside functional indicators such as sleep quality and daily activity.
Researchers caution that early results remain preliminary and emphasize the need for larger, controlled trials.
Regulators continue to stress safety monitoring and clear labeling as studies move into broader enrollment phases.